Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Tharimmune (NASDAQ:THAR) has appointed Vincent LoPriore to its Board of Directors, expanding the board to seven members. LoPriore, Founder of Gravitas Capital and Co-Founder of President Street Global, brings three decades of finance and strategic leadership experience to the clinical-stage biotech company.
As a senior executive at Gravitas Capital, LoPriore specialized in healthcare and biotech portfolios, managing over $150 million in investment funds and participating in investments exceeding $500 million. His appointment aims to support Tharimmune's next growth phase, product development, and commitment to enhancing leadership with experienced financial professionals.
The strategic addition aligns with Tharimmune's focus on advancing clinical programs, deepening licensing relationships, and building a sustainable pipeline in immunology and oncology.
Tharimmune (NASDAQ:THAR) ha nominato Vincent LoPriore nel proprio Consiglio di Amministrazione, ampliando il consiglio a sette membri. LoPriore, fondatore di Gravitas Capital e co-fondatore di President Street Global, porta con sé trent'anni di esperienza nella finanza e nella leadership strategica in una società biotech in fase clinica.
Come dirigente senior di Gravitas Capital, LoPriore si è specializzato in portafogli healthcare e biotech, gestendo oltre 150 milioni di dollari in fondi d'investimento e partecipando a investimenti per più di 500 milioni di dollari. La sua nomina punta a sostenere la prossima fase di crescita di Tharimmune, lo sviluppo dei prodotti e il rafforzamento della leadership con professionisti finanziari esperti.
Questa aggiunta strategica è in linea con l’obiettivo di Tharimmune di far progredire i programmi clinici, approfondire le relazioni di licensing e costruire un portafoglio sostenibile nei settori dell’immunologia e dell’oncologia.
Tharimmune (NASDAQ:THAR) ha nombrado a Vincent LoPriore en su Junta Directiva, ampliando el consejo a siete miembros. LoPriore, fundador de Gravitas Capital y cofundador de President Street Global, aporta tres décadas de experiencia en finanzas y liderazgo estratégico a esta empresa biotecnológica en fase clínica.
Como ejecutivo senior en Gravitas Capital, LoPriore se especializó en carteras de salud y biotecnología, gestionando más de 150 millones de dólares en fondos de inversión y participando en inversiones que superan los 500 millones de dólares. Su nombramiento busca apoyar la próxima fase de crecimiento de Tharimmune, el desarrollo de productos y el compromiso de reforzar el liderazgo con profesionales financieros experimentados.
Esta incorporación estratégica está alineada con el enfoque de Tharimmune en avanzar sus programas clínicos, profundizar las relaciones de licenciamiento y construir una cartera sostenible en inmunología y oncología.
Tharimmune (NASDAQ:THAR)는 이사회 멤버를 7명으로 확대하며 Vincent LoPriore를 이사회에 임명했습니다. Gravitas Capital의 창립자이자 President Street Global의 공동 창립자인 LoPriore는 임상 단계 바이오텍 회사에 30년간의 금융 및 전략적 리더십 경험을 제공합니다.
Gravitas Capital의 고위 임원으로서 LoPriore는 헬스케어 및 바이오텍 포트폴리오를 전문으로 하여 1억 5천만 달러 이상의 투자 펀드를 관리하고 5억 달러가 넘는 투자에 참여했습니다. 그의 임명은 Tharimmune의 다음 성장 단계, 제품 개발, 그리고 경험 많은 금융 전문가들과의 리더십 강화에 기여할 것입니다.
이 전략적 영입은 Tharimmune이 임상 프로그램을 진전시키고, 라이선스 관계를 심화하며, 면역학 및 종양학 분야에서 지속 가능한 파이프라인을 구축하려는 목표와 부합합니다.
Tharimmune (NASDAQ:THAR) a nommé Vincent LoPriore au sein de son Conseil d'administration, portant le nombre de membres à sept. LoPriore, fondateur de Gravitas Capital et cofondateur de President Street Global, apporte trois décennies d'expérience en finance et en leadership stratégique à cette société biotechnologique en phase clinique.
En tant que cadre supérieur chez Gravitas Capital, LoPriore s'est spécialisé dans les portefeuilles santé et biotechnologie, gérant plus de 150 millions de dollars de fonds d'investissement et participant à des investissements dépassant 500 millions de dollars. Sa nomination vise à soutenir la prochaine phase de croissance de Tharimmune, le développement des produits et l'engagement à renforcer la direction avec des professionnels financiers expérimentés.
Cette nomination stratégique s'aligne sur l'objectif de Tharimmune de faire progresser ses programmes cliniques, d'approfondir ses relations de licence et de construire un pipeline durable en immunologie et en oncologie.
Tharimmune (NASDAQ:THAR) hat Vincent LoPriore in den Vorstand berufen und damit das Board auf sieben Mitglieder erweitert. LoPriore, Gründer von Gravitas Capital und Mitbegründer von President Street Global, bringt drei Jahrzehnte Erfahrung in Finanzen und strategischer Führung in das klinisch orientierte Biotechnologieunternehmen ein.
Als leitender Geschäftsführer bei Gravitas Capital spezialisierte sich LoPriore auf Healthcare- und Biotech-Portfolios, verwaltete über 150 Millionen US-Dollar an Investmentfonds und war an Investitionen von mehr als 500 Millionen US-Dollar beteiligt. Seine Ernennung soll Tharimmune in der nächsten Wachstumsphase, der Produktentwicklung und der Stärkung der Führungsebene mit erfahrenen Finanzexperten unterstützen.
Diese strategische Ergänzung steht im Einklang mit Tharimmunes Fokus auf die Weiterentwicklung klinischer Programme, die Vertiefung von Lizenzpartnerschaften und den Aufbau einer nachhaltigen Pipeline in den Bereichen Immunologie und Onkologie.
- Addition of experienced financial executive with $500M+ investment track record
- Strategic expansion of board expertise in healthcare and biotech sectors
- Enhanced capability for capital raising and business development
- None.
BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas Capital and Co-Founder of President Street Global, to its Board of Directors, increasing the size of the Board to seven Directors.
This appointment strengthens Tharimmune's strategic leadership and will support the company's next phase of growth and product development. It also underscores Tharimmune's commitment to enhancing its leadership team with experienced financial professionals as the company advances key clinical programs, deepens its licensing relationships and builds a pipeline for long-term, sustainable growth.
"On behalf of the Board, I'm delighted to welcome Vincent as our newest Director," said Randy Milby, Chairman of the Board. "His decades of experience in financial markets, investment strategy and business development, along with a broad network of industry relationships will be valuable as we advance our pipeline of cutting-edge immunotherapies. In addition, his focus on maximizing shareholder value at this important phase in our company's evolution is aligned with management's, while his proven track record in guiding companies through significant milestones supports our commitment to transforming patient care and accelerating innovation."
Mr. LoPriore brings to Tharimmune three decades of experience in finance and strategic leadership, most recently serving as a senior executive at Gravitas Capital, where he specialized in building and scaling healthcare and biotech portfolios. Mr. LoPriore has closed on over
"I'm honored to join the Tharimmune Board," said Mr. LoPriore. "The team is clearly committed to addressing unmet medical needs while building value for shareholders. Tharimmune's dedication to advancing breakthrough therapies complements my passion for supporting businesses that drive meaningful, positive impacts on patients' lives. I look forward to collaborating with my fellow Directors and company professionals to drive success."
About Vincent LoPriore
Mr. LoPriore is a seasoned financial professional with more than 30 years of experience in investment banking, private placements and institutional capital markets. He began his career at Oppenheimer & Co. and subsequently held senior positions at Legg Mason, C.E. Unterberg Towbin and several boutique investment firms. At C.E. Unterberg Towbin, he served as a Partner and Co-Founder of the firm's Special Securities Group, where he led strategic capital transactions and helped close over
He is the Founder and Investment Manager of Gravitas Capital LP, a hedge fund known for its strong historical performance that participated in Tharimmune's two most recent PIPE financings. Additionally, Mr. LoPriore is a licensed broker with President Street Global, LLC, a FINRA-registered broker-dealer, and a partner of the firm's holding company. He continues to advise growth-stage businesses on strategic capital raises and institutional investor engagement.
Mr. LoPriore is also involved in philanthropic initiatives including Race to Erase MS and Cure Addiction Now.
About Tharimmune, Inc.
Tharimmune, Inc. is a clinical-stage biotechnology company focused on advancing innovative therapies in immunology, inflammation, and oncology. Its lead program, TH104, is being developed to treat chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease. The pipeline also includes TH023, an oral TNF-alpha inhibitor for autoimmune disorders, as well as early-stage multispecific biologics leveraging its proprietary EpiClick ™ Technology.
In addition to novel drug candidates, Tharimmune is also focused on developing new delivery methods for well-established medications - with the goal of improving therapeutic efficacy and reducing side effects. The company holds a license agreement with OmniAb, Inc., granting access to next-generation antibody discovery platforms.
Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.
Contacts
Tharimmune, Inc.
ir@tharimmune.com
Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
FAQ
What experience does Vincent LoPriore bring to Tharimmune's (THAR) Board of Directors?
How many directors are now on Tharimmune's (THAR) board after LoPriore's appointment?
What strategic goals is Tharimmune (THAR) pursuing with this board appointment?
What is Vincent LoPriore's background in healthcare investments at Tharimmune (THAR)?
